TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

NCT04561986 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

50

Enrollment

OTHER_GOV

Sponsor class

Conditions

Antibody-mediated Rejection

Interventions

DRUG: Tocilizumab

Sponsor

Vastra Gotaland Region

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]